🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Dupixent and Narrowband UVB for Atopic Dermatitis

RecruitingPhase 4Ages 18 Years - anyAllPsoriasis Treatment Center of Central New Jersey
NCT05285839 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Male or female adult ≥ 18 years of age; * Diagnosis of moderate to severe atopic dermatitis as defined at baseline by: * EASI score of 16 or greater, * IGA score of 3 or greater * BSA of 10% or greater, Exclusion Criteria: * Subjects with previous exposure to dupilumab. * Known or suspected hypersensitivity to dupilumab or any of its excipients. * History of photosensitivity.
💊

What it tests

  • Dupixent
📍

Where

1 site
Eczema Treatment Center of New Jersey
East Windsor, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy